Abstract:The severe acute respiratory syndrome coronavirus (SARS-CoV) caused a worldwide epidemic in late 2002/early 2003 and a second outbreak in the winter of 2003/2004 by an independent animal-to-human transmission. The GD03 strain, which was isolated from an index patient of the second outbreak, was reported to resist neutralization by the human monoclonal antibodies (hmAbs) 80R and S3.1, which can potently neutralize isolates from the first outbreak. Here we report that two hmAbs, m396 and S230.15, potently neutralized GD03 and representative isolates from the first SARS outbreak (Urbani, Tor2) and from palm civets (SZ3, SZ16). These antibodies also protected mice challenged with the Urbani or recombinant viruses bearing the GD03 and SZ16 spike (S) glycoproteins. Both antibodies competed with the SARS-CoV receptor, ACE2, for binding to the receptor-binding domain (RBD), suggesting a mechanism of neutralization that involves interference with the SARS-CoV-ACE2 interaction. Two putative hot-spot residues in the RBD (Ile-489 and Tyr-491) were identified within the SARS-CoV spike that likely contribute to most of the m396-binding energy. Residues Ile-489 and Tyr-491 are highly conserved within the SARS-CoV spike, indicating a possible mechanism of the m396 cross-reactivity. Sequence analysis and mutagenesis data show that m396 might neutralize all zoonotic and epidemic SARS-CoV isolates with known sequences, except strains derived from bats. These antibodies exhibit cross-reactivity against isolates from the two SARS outbreaks and palm civets and could have potential applications for diagnosis, prophylaxis, and treatment of SARS-CoV infections.

Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice

Designed mosaic nanoparticles enhance cross-reactive immune responses in mice

Mosaic sarbecovirus nanoparticles elicit cross-reactive responses in pre-vaccinated animals

Mosaic RBD Nanoparticles Elicit Protective Immunity Against Multiple Human Coronaviruses in Animal Models

Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models

Mosaic RBD nanoparticles protect against multiple sarbecovirus challenges in animal models

Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses

Cross-species recognition of bat coronavirus RsYN04 and cross-reaction of SARS-CoV-2 antibodies against the virus

Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses

Exploration of the cross-immunity between SARS-CoV and SARS-CoV-2 in mice

Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses

Quadrivalent mosaic HexaPro-bearing nanoparticle vaccine protects against infection of SARS-CoV-2 variants

Distinct sensitivities to SARS-CoV-2 variants in vaccinated humans and mice

Two Pan-Sars-cov-2 Nanobodies and Their Multivalent Derivatives Effectively Prevent Omicron Infections in Mice.

A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice

A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration

Potent Cross-Reactive Neutralization of SARS Coronavirus Isolates by Human Monoclonal Antibodies.

Mosaic RBD nanoparticle elicits immunodominant antibody responses across sarbecoviruses

Antigen-Heterologous Vaccination Regimen Triggers Alternate Antibody Targeting in SARS-CoV-2-DNA-Vaccinated Mice

Antibody-Dependent Complement Responses toward SARS-CoV-2 Receptor-Binding Domain Immobilized on “Pseudovirus-like” Nanoparticles